Merck & Co., Inc. (MRK)
| Market Cap | 300.73B |
| Revenue (ttm) | 62.48B |
| Net Income (ttm) | 13.74B |
| Shares Out | 2.53B |
| EPS (ttm) | 5.39 |
| PE Ratio | 22.03 |
| Forward PE | 13.90 |
| Dividend | $3.08 (2.60%) |
| Ex-Dividend Date | Sep 16, 2024 |
| Volume | 9,605,161 |
| Open | 118.20 |
| Previous Close | 118.29 |
| Day's Range | 117.87 - 119.37 |
| 52-Week Range | 99.14 - 134.63 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 134.58 (+13.44%) |
| Earnings Date | Oct 24, 2024 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv... [Read more]
Financial Performance
In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $134.58, which is an increase of 13.44% from the latest price.
News
Merck & Co., Inc. (MRK) Bank of America Global Healthcare Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK) Bank of America Global Healthcare Conference September 18, 2024 6:40 AM ET Company Participants Joseph Romanelli - President, Human Health International Peter Dannenbaum ...
Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated with ...
FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA,...
Daiichi Sankyo and Merck's cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug met the main goal in a late-stage study in patients with lung cancer.
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
LONDON--(BUSINESS WIRE)---- $MRK #Biotech--Summit Therapeutics' Breakthrough with Ivonescimab The recent breakthrough with Summit Therapeutics' Ivonescimab (SMT112) reverberated not just in the medica...
Buy 9 Sustainable Dividend Dogs From Barron's August 100
Calvert Research and Management evaluated 1,000 large companies on 230 ESG indicators to rank the top 100 most sustainable companies for Barron's annual list. Nine dividend-paying ESG companies, inclu...
Ten-Year Data for Merck's KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data from the pivotal Phase 3 KEYN...
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus LENVIMA in Combination With TACE Significantly Improved PFS Compared to TACE Alone in Patients With Unresectable, Non-Metastat...
Merck's KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA® Plus CRT Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer.
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA plus trastuzumab and chemotherapy OS results as first-line treatment in patients with HER2-positive advanced gastric or GEJ adenocarcinoma.
Merck Appears Ready To Return To June Highs (Technical Analysis)
Merck's 15% decline in July is presenting investors with an intermediate to long-term buying opportunity. Long-term trend lines and Bollinger Bands indicate strong support at $110. We expect Merck to ...
Trade It or Fade It: The week's big biotech moves
Jared Holz, Mizuho, joins 'Fast Money' to talk his playbook on recent biotech movers.
Merck Unveils New MAVENCLAD® Four-Year Data Highlighting Benefits of Early Treatment and Sustained Efficacy Across Multiple Measures of Disease Activity
DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced presentations showcasing the long-term safety prof...
Merck to Participate in the Bank of America 2024 Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Bank of America 2024 Global Healthcare Conference.
Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males.
BA Reaches Union Deal, COST Price Target Hike, MRK Down as SMMT Rallies
A tentative deal between Boeing (BA) and the International Aerospace Machinists union could avoid a strike. Costco (COST) receives another price target hike.
Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped Merck's ...
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Sunday, Summit Therapeutics Inc. SMMT released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc.
Merck Stock Falls After Rival Beats Keytruda Cancer Drug in Trial
Summit Therapeutics said its Ivonescimab treatment reduced the risk of disease progression or death by 49% compared with the market leader.
Merck & Co., Inc. (MRK) CEO Rob Davis presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 2:35 PM ET Company Participants Rob Davis - Chairman and CEO Dean Li - President of Merck Resear...
Why Did Merck Stock Rise 65%?
Merck stock (NYSE: MRK) has gained over 65% in value since early January 2021 – jumping from levels of $70 then to around $115 now – vs. an increase of about 50% for the S&P 500 over this period.
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for four approved medicines and six pipeline candida...
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co., Inc., Rahway, N.J., USA, today announced t...
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories.